# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...
Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Pr...
Jefferies analyst Tycho Peterson assumes Nautilus Biotechnology (NASDAQ:NAUT) with a Hold rating and lowers Price Target of $3.
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate o...
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...